Capital Readiness vs Growth Readiness

By Andy Sloan

4 April 2026 · 4 min read

There is a number that gets cited in almost every dental group boardroom conversation I have been part of.

It is the revenue number. Sometimes it is the EBITDA number. Occasionally it is the site count. What it almost never is, until it is too late, is the quality number.

This is the central confusion at the heart of PE-backed dental consolidation in the UK. Revenue growth and business quality are not the same thing. They can travel together for a while, and in a buoyant market with cheap capital and willing vendors, they often do. But when conditions tighten, when the regulatory environment shifts, when the cost of debt rises, when an acquirer starts asking harder questions, the gap between them becomes visible very quickly.

And in UK dentistry right now, conditions are tightening.

The distinction that matters

Capital readiness is the ability to attract investment, survive due diligence, and achieve a valuation that reflects the genuine quality of the business. It is about being legible to investors, regulators and acquirers in a way that creates confidence rather than questions.

Growth readiness is something different. It is the operational capacity to scale without degrading quality, to add practices without adding complexity, to grow revenue without growing risk.

Most dental groups that reach the 10 to 30 site mark have achieved some version of growth readiness. They have demonstrated the ability to acquire and integrate. What they have not always achieved is capital readiness, and the difference only becomes apparent when they try to transact.

What due diligence actually finds

I have been involved in or observed more than 100 transactions across dental practices and healthcare technology businesses. The pattern in due diligence is remarkably consistent.

Revenue is usually as presented. EBITDA is sometimes less clean than the management accounts suggest. Normalisation adjustments, associate cost structures that do not survive scrutiny, occupancy costs that were managed down ahead of a process. But these are negotiating points, not deal-breakers.

What creates real problems, what chips valuation, extends timelines, and occasionally kills transactions, is governance. Specifically the absence of it.

Groups that cannot demonstrate consistent compliance across every site. Groups whose associate pay models are undocumented, inconsistent, or disputed. Groups that have no reliable data on clinical quality, patient outcomes, or workforce performance. Groups where the operating model exists in the founder's head rather than in documented, transferable systems.

These are not small issues. They are the things that separate a 7x EBITDA outcome from a 10x one. They are the things that determine whether a process runs for four months or twelve. And they are almost entirely within the control of the management team, if they start building for them early enough.

The regulatory dimension

The CMA's market study into private dentistry, launched in March 2026, adds a new layer to this picture.

The veterinary market study, a near-identical process that began in September 2023 and concluded with a final report on 25 March 2026, produced mandatory transparency requirements, pricing disclosure obligations, and heightened scrutiny of acquisition practices. The dental inquiry is following the same path.

For PE-backed dental groups, this matters in two ways. First, the compliance burden will increase, and groups that have invested in compliance infrastructure will absorb that burden more efficiently than those that have not. Second, the reputational dimension of regulatory scrutiny will affect how institutional investors evaluate the sector. Groups that can demonstrate proactive governance rather than reactive compliance will be positioned as the quality end of a market that is about to be more carefully examined.

The investors who understand this are already asking different questions in due diligence. The groups that understand it are already building differently.

What capital readiness actually looks like

It is not a set of documents produced ahead of a process. It is an operating culture that makes those documents a natural output rather than a retrospective exercise.

Capital ready dental groups have compliance systems that are auditable at the site level, consistently applied, and reported at board level. They have associate pay models that are documented, transparent, and trusted by their clinical teams. They have data infrastructure that gives management and any incoming investor a real-time picture of performance across every site. And they have governance frameworks that demonstrate independent thinking at board level, not just founder decision-making ratified after the fact.

None of this is complicated. All of it takes time. And the groups that start building it at five sites have a fundamentally different position at twenty sites than those that wait until they are preparing for a transaction.

The question worth asking now

If an acquirer or institutional investor walked into your business tomorrow and asked to see three years of compliance audit data, your associate pay model documentation, and your board minutes, what would they find?

For most dental groups, the honest answer is: not enough.

That gap is closeable. But it closes slowly, and only if you start now.

Next read: The three prices of a dental business →